Table 1.
Natural small-molecule drugs for sepsis treatment.
| Compound | Model | Improvement | Adverse Reaction | Research Progress |
|---|---|---|---|---|
| Resveratrol | CLP/LPS | SAKI/SAE/ALI/cardiomyocyte injury | High doses can increase intracellular oxidation | Animal experiment |
| Curcumin | CLP/LPS | SAKI/ALI | Animal experiment | |
| Tetrahydrocurcumin | CLP | SAKI | Animal experiment | |
| Emodin | CLP/LPS | ALI/IMI/cognitive dysfunction | Animal experiment | |
| Aloin | CLP/LPS | SAKI/ALI | Animal experiment | |
| Salidroside | CLP/LPS | SAKI/ALI/myocardial injury | Animal experiment | |
| Geniposide | CLP/LPS | SAKI/myocardial dysfunction | Animal experiment | |
| Ginsenoside | CLP/LPS | Inflammatory response and organ damage | Animal experiment | |
| Breviscapine | CME | Myocardium inflammation | Animal experiment | |
| Baicalein | CLP/LPS | ALI/SLI | Animal experiment | |
| Diosmtin | LPS | SAKI/ALI | Cell experiment | |
| Agmatine | LPS | Vascular dysfunction/systemic inflammation and organ failure | Animal experiment | |
| Kukoamine B | LPS | Inflammation | clinical trials | |
| Matrine | CLP/LPS | Cardiac insufficiency | Animal experiment | |
| Anisodamine hydrobromide | LPS | SAKI/ALI | Animal experiment | |
| Berberine | CLP/LPS | Cardiac dysfunction, myocardial injury, and intestinal vascular barrier dysfunction | Animal experiment | |
| Leonurine | LPS | ALI/myocarditis | Animal experiment | |
| Glutamine | CLP | Damage to the intestinal mucosa, kidney, and liver tissues | Clinical trials |